Luca Moscetti

3.8k total citations · 1 hit paper
98 papers, 1.6k citations indexed

About

Luca Moscetti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Luca Moscetti has authored 98 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 30 papers in Cancer Research. Recurrent topics in Luca Moscetti's work include Advanced Breast Cancer Therapies (30 papers), Cancer Treatment and Pharmacology (25 papers) and HER2/EGFR in Cancer Research (24 papers). Luca Moscetti is often cited by papers focused on Advanced Breast Cancer Therapies (30 papers), Cancer Treatment and Pharmacology (25 papers) and HER2/EGFR in Cancer Research (24 papers). Luca Moscetti collaborates with scholars based in Italy, Malaysia and Spain. Luca Moscetti's co-authors include Isabella Sperduti, Claudia Omarini, Federico Piacentini, Flavia Longo, Calogero Lauricella, Massimo Broggini, Mirko Marabese, Marina Chiara Garassino, Gabriella Farina and Eliana Rulli and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Luca Moscetti

90 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

2013 376 citations Marina Chiara Garassino, Olga Martelli et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luca Moscetti Italy	20	1.1k	873	361	355	101	98	1.6k
Jackie Walling United States	16	1.0k 0.9×	878 1.0×	252 0.7×	671 1.9×	81 0.8×	45	1.9k
Adam J. Schoenfeld United States	23	1.5k 1.3×	1.0k 1.2×	330 0.9×	576 1.6×	75 0.7×	77	2.3k
Penelope A. Bradbury Canada	29	1.1k 0.9×	1.1k 1.3×	419 1.2×	604 1.7×	99 1.0×	112	2.0k
Faith E. Nathan United States	23	1.4k 1.2×	1.2k 1.4×	317 0.9×	356 1.0×	188 1.9×	45	2.1k
Pascale Tomasini France	22	1.1k 1.0×	1.1k 1.3×	425 1.2×	465 1.3×	95 0.9×	109	1.8k
Maria Q. Baggstrom United States	17	743 0.6×	922 1.1×	300 0.8×	406 1.1×	152 1.5×	65	1.5k
Fábio Franke United States	19	1.3k 1.2×	1.4k 1.6×	535 1.5×	558 1.6×	65 0.6×	54	2.0k
Amelia Insa Spain	18	1.1k 0.9×	697 0.8×	277 0.8×	317 0.9×	68 0.7×	63	1.5k
Ryan D. Gentzler United States	20	2.1k 1.8×	1.4k 1.6×	219 0.6×	285 0.8×	70 0.7×	86	2.5k
Zhongsheng Tong China	20	1.2k 1.1×	754 0.9×	372 1.0×	324 0.9×	264 2.6×	105	1.7k

Countries citing papers authored by Luca Moscetti

Since Specialization

Citations

This map shows the geographic impact of Luca Moscetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Moscetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Moscetti more than expected).

Fields of papers citing papers by Luca Moscetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Moscetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Moscetti. The network helps show where Luca Moscetti may publish in the future.

Co-authorship network of co-authors of Luca Moscetti

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Moscetti. A scholar is included among the top collaborators of Luca Moscetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Moscetti. Luca Moscetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Farina, Alessandro, Federica Caggia, Monica Barbolini, et al.. (2025). Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments. Breast Cancer Targets and Therapy. Volume 17. 53–66. 1 indexed citations

Mayer, Erik N., M.V. Martín, Gregory A. Vidal, et al.. (2025). LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. Annals of Oncology. 36. S1561–S1562. 2 indexed citations

Moscetti, Luca, Isabella Sperduti, Elena Barbieri, et al.. (2024). Abstract PO1-05-02: CDK4/6 inhibitors in advanced breast cancer (aBC). Preliminary results of the CDK4/6i choice and sequence of treatments in a series of 174 patients. GOIRC-04-2019 retro/prospective observational study. Cancer Research. 84(9_Supplement). PO1–5. 1 indexed citations

Bettelli, Stefania, Monica Barbolini, Luca Moscetti, et al.. (2024). Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients. International Journal of Molecular Sciences. 25(5). 2490–2490. 1 indexed citations

Toss, Angela, Luca Moscetti, Enza Di Palma, et al.. (2023). Management ofPALB2‐associated breast cancer: A literature review and case report. SHILAP Revista de lepidopterología. 11(8). e7747–e7747. 7 indexed citations

Cerma, Krisida, Federico Piacentini, Luca Moscetti, et al.. (2023). Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. Biomedicines. 11(1). 109–109. 58 indexed citations

Omarini, Claudia, Angela Toss, Isabella Sperduti, et al.. (2023). Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting. Clinical Breast Cancer. 23(7). 712–720.e3.

Omarini, Claudia, et al.. (2022). Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist. Clinical Breast Cancer. 22(4). 289–299. 7 indexed citations

Piacentini, Federico, Ilenia Mastrolia, Valentina Masciale, et al.. (2021). Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. Cancers. 13(19). 4894–4894. 8 indexed citations

10.

Nelli, Fabrizio, Agnese Fabbri, Luca Moscetti, et al.. (2020). Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. Recenti Progressi in Medicina. 111(12). 761–768. 2 indexed citations

11.

Omarini, Claudia, Annarita Pecchi, Sara Balduzzi, et al.. (2019). <p>Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy</p>. Cancer Management and Research. Volume 11. 9563–9569. 20 indexed citations

12.

Toss, Angela, Marta Venturelli, Isabella Sperduti, et al.. (2019). First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. Clinical Breast Cancer. 19(6). e701–e716. 7 indexed citations

13.

Omarini, Claudia, Stefania Bettelli, Shaniko Kaleci, et al.. (2018). Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. BioMed Research International. 2018. 1–8. 8 indexed citations

14.

Omarini, Claudia, Giorgia Guaitoli, Stefania Pipitone, et al.. (2018). Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Management and Research. Volume 10. 91–103. 56 indexed citations

15.

Fabi, Alessandra, Diana Giannarelli, Luca Moscetti, et al.. (2017). Ado-Trastuzumab Emtansine (T-DM1) in HER2+ Advanced Breast Cancer Patients: does Pretreatment with Pertuzumab Matter?. Future Oncology. 13(30). 2791–2797. 20 indexed citations

16.

Moscetti, Luca, Patrizia Vici, Isabella Sperduti, et al.. (2015). Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC). Annals of Oncology. 26. vi13–vi13. 1 indexed citations

17.

Giorgi, Ugo De, Karim Rihawi, Michele Aieta, et al.. (2014). Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. Journal of Geriatric Oncology. 5(2). 156–163. 22 indexed citations

18.

Farina, Gabriella, Flavia Longo, Olga Martelli, et al.. (2011). Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer. 12(2). 138–141. 13 indexed citations

19.

Grossi, Francesco, Filippo de Marinis, Vittorio Gebbia, et al.. (2011). A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 69(2). 369–375. 3 indexed citations

20.

Cortesi, Enrico, et al.. (2001). Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15. Lung Cancer. 31(2-3). 271–276. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact